undefined undefined
NaN.000
NaN.00%
加拿大投资银行集团:维持Pulmonx(LUNG.US)评级,由买入调整至买入评级, 目标价由16.00美元调整至15.00美元。
05-03 03:21
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thu...
05-02 22:28
Gainers: Allarity Therapeutics (ALLR) +133% Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer. Emergent BioSolutions (...
05-02 20:43
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical benefit, leading to early conclusion of the Phase 2 trial in advanced ovarian
05-02 20:39
Gainers: Pulmonx Corporation (LUNG) +23%. Enovix Corporation (ENVX) +21%. C.H. Robinson Worldwide (CHRW) +14%. Vroom (VRM) +10%. CRISPR Therapeutics (CRSP) +10%. Losers: Remitly Global (RELY) -22%. Ev...
05-02 05:27
Pulmonx press release (NASDAQ:LUNG): Q1 GAAP EPS of -$0.36. Revenue of $18.9M (+30.3% Y/Y). Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million....
05-02 05:21
Piper Sandler analyst Jason Bednar reiterates Pulmonx (NASDAQ:LUNG) with a Overweight and maintains $17 price target.
04-04 00:05
Pulmonx (NASDAQ:LUNG) on Tuesday announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi succeeds John McKune, who has served as the company’s interim CFO s...
04-03 04:10
3月10日晚间,百利天恒发布公告,继去年12月披露潜在同类首创EGFR/HER3双特异性抗体偶联药物(ADC)BL-B01D1实现“License out”(授...
03-11 20:44
Analysts' ratings for Pulmonx (NASDAQ:LUNG) over the last quarter vary from bul...
02-23 20:00